Shares of International Biotechnology (LON:IBT - Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 689.46 ($8.61) and traded as high as GBX 734 ($9.16). International Biotechnology shares last traded at GBX 726 ($9.06), with a volume of 74,465 shares trading hands.
International Biotechnology Price Performance
The firm has a market capitalization of £263.89 million, a price-to-earnings ratio of 1,487.50 and a beta of 0.21. The company's 50 day moving average is GBX 699.27 and its 200 day moving average is GBX 690.15. The company has a quick ratio of 0.32, a current ratio of 0.46 and a debt-to-equity ratio of 9.66.
International Biotechnology (LON:IBT - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported GBX (9.16) (($0.11)) earnings per share (EPS) for the quarter. International Biotechnology had a return on equity of 6.25% and a net margin of 75.33%. On average, equities research analysts anticipate that International Biotechnology will post 0.9435943 earnings per share for the current fiscal year.
International Biotechnology Increases Dividend
The business also recently declared a dividend, which was paid on Friday, January 24th. Investors of record on Thursday, December 19th were given a dividend of GBX 15.56 ($0.19) per share. The ex-dividend date of this dividend was Thursday, December 19th. This represents a yield of 2.21%. This is an increase from International Biotechnology's previous dividend of $14.50. International Biotechnology's dividend payout ratio is currently 6,041.67%.
Insiders Place Their Bets
In other news, insider Katherine Cornish-Bowden purchased 1,500 shares of the business's stock in a transaction dated Tuesday, December 17th. The stock was bought at an average price of GBX 713 ($8.90) per share, with a total value of £10,695 ($13,348.73). Corporate insiders own 4.18% of the company's stock.
International Biotechnology Company Profile
(
Get Free Report)
The Company's investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies.
The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.
Featured Stories
Before you consider International Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and International Biotechnology wasn't on the list.
While International Biotechnology currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
